Core Viewpoint - The company, Microtech Medical-B (02235), has received approval for its LinX continuous glucose monitoring system in Brazil, which is expected to enhance its market presence in Latin America and drive revenue growth [1]. Group 1: Company Performance - As of December 24, 2025, the stock closed at 7.68 yuan, reflecting a 0.52% increase from the previous trading day [1]. - The stock's 52-week high is 9.17 yuan, while the low is 4.0 yuan [1]. Group 2: Market Opportunity - Brazil is identified as a core market in Latin America, with approximately 16.62 million diabetes patients aged 20-79, representing a prevalence rate of 10.7%, ranking sixth globally [1]. - Diabetes-related expenditures in Brazil are projected to reach approximately $45.1 billion in 2024, making it the third highest globally [1]. Group 3: Strategic Focus - The company aims to continue focusing on technological innovation and global development in the diabetes monitoring, treatment, and management sectors [1].
微泰医疗-B（02235.HK）披露持续葡萄糖监测系统海外获批，12月24日股价上涨0.52%